The impact of adenovirus infection on the immunocompromised host
- PMID: 12740831
- DOI: 10.1002/rmv.386
The impact of adenovirus infection on the immunocompromised host
Abstract
Adenovirus (Ad) infections in immunocompromised hosts have increased in frequency as the number of patients with transplants of bone marrow, liver, kidney, heart and other organs increase in number and survive longer. The numbers of such patients have also increased because of the emergence of the HIV epidemic. Ad infections with the 51 different serotypes recognised to date have few pathognomonic signs and symptoms, and thus require a variety of laboratory-based procedures to confirm infection. These viruses have the ability to target various organs with relative serotype specificity and can cause diverse manifestations including serious life-threatening diseases characteristic of the organs involved. Ads have cytolytic and immunoregulatory properties. The clinical dilemma remains the prompt recognition of Ad-related disease, the differentiation of Ad infection from Ad disease and the differentiation from other causative agents. Since the armamentarium of effective antiviral agents available to treat Ads is unproven by controlled trials and the virus is often not acquired de novo, it is difficult to prevent reactivation in immunodeficient hosts or new acquisition from donor organs. Timely discontinuation of immunosuppressive agents is necessary to prevent morbid outcomes. The clinical diseases, diagnostic tests, antiviral agents and biological aspects of the Ads as pathogens in immunocompromised patients are discussed in the context of this review. Some of the newer diagnostic tests are based on the well-studied molecular biology of Ads, which also have been attenuated by selective viral DNA deletions for use as vectors in numerous gene therapy trials in humans.
Copyright 2003 John Wiley & Sons, Ltd.
Similar articles
-
Clinical features and treatment of adenovirus infections.Rev Med Virol. 2008 Nov-Dec;18(6):357-74. doi: 10.1002/rmv.589. Rev Med Virol. 2008. PMID: 18655013 Review.
-
[Adenovirus infections in immunocompromised patients].Orv Hetil. 2012 Dec 2;153(48):1896-904. doi: 10.1556/OH.2012.29496. Orv Hetil. 2012. PMID: 23183005 Review. Hungarian.
-
[Tuberculosis in compromised hosts].Kekkaku. 2003 Nov;78(11):717-22. Kekkaku. 2003. PMID: 14672050 Japanese.
-
[Development of antituberculous drugs: current status and future prospects].Kekkaku. 2006 Dec;81(12):753-74. Kekkaku. 2006. PMID: 17240921 Review. Japanese.
-
[Clinical picture of Herpesviridae infections among immunocompromised patients: bone marrow and solid organ transplants recipients].Przegl Epidemiol. 2003;57(2):289-97. Przegl Epidemiol. 2003. PMID: 12910597 Polish.
Cited by
-
Macropinocytotic uptake and infection of human epithelial cells with species B2 adenovirus type 35.J Virol. 2010 May;84(10):5336-50. doi: 10.1128/JVI.02494-09. Epub 2010 Mar 17. J Virol. 2010. PMID: 20237079 Free PMC article.
-
Virus reactivation: a panoramic view in human infections.Future Virol. 2011 Apr;6(4):451-463. doi: 10.2217/fvl.11.21. Future Virol. 2011. PMID: 21799704 Free PMC article.
-
Recent Advances in Novel Antiviral Therapies against Human Adenovirus.Microorganisms. 2020 Aug 22;8(9):1284. doi: 10.3390/microorganisms8091284. Microorganisms. 2020. PMID: 32842697 Free PMC article. Review.
-
Anticancer activity of oncolytic adenovirus vector armed with IFN-alpha and ADP is enhanced by pharmacologically controlled expression of TRAIL.Cancer Gene Ther. 2008 Feb;15(2):61-72. doi: 10.1038/sj.cgt.7701107. Epub 2007 Nov 9. Cancer Gene Ther. 2008. PMID: 17992200 Free PMC article.
-
CD46 is a cellular receptor for all species B adenoviruses except types 3 and 7.J Virol. 2005 Nov;79(22):14429-36. doi: 10.1128/JVI.79.22.14429-14436.2005. J Virol. 2005. PMID: 16254377 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources